The active sites of bovine insulin-like growth factor (IGF) I and II fragments were studied. Overlapping fragments of IGF I (residues 1-25, 11-35, 21-45, 31-55, and 41-70) and of IGF II (residues 1-24, 10-34, 20-44, 30-54, and 40-67) were chemically synthesized. The activity of the fragments was measured by stimulating the proliferation of rat L6 myoblast cells. Two fragments of IGF I (residues 21-45 and 31-55) and two fragments of IGF II (residues 20-44 and 30-54) were active while the other fragments were inactive in stimulating cell proliferation. Although the activity of these fragments was observed only at a high concentration of 0.1 mM, the results imply that the active site is located around residues 31-45 for IGF I fragments and residues 30-44 for IGF II fragments. Consequently, an IGF I fragment (residues 26-50) having a five-residue extension to both the N- and C-terminal sites of residues 31-45 also stimulated the proliferation of L6 myoblast cells. Furthermore, the substitution of Ile-35 in two IGF II fragments (residues 21-45 and 31-55) by Ser inactivated these fragments. This suggests that Ile-35 is an essential residue for IGF II fragment activity. Ser-35, which was reported in the original sequencing of bovine IGF II, is incorrect in the sequence and furthermore has been consistently found to be an Ile-35 in our hands.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi00448a028DOI Listing

Publication Analysis

Top Keywords

igf fragments
16
igf residues
16
fragments
12
myoblast cells
12
fragments igf
12
21-45 31-55
12
igf
11
residues
9
bovine insulin-like
8
insulin-like growth
8

Similar Publications

Background: Fluoroethylnormemantine (FENM), a new Memantine (MEM) derivative, prevented amyloid-β[25-35] peptide (Aβ)-induced neurotoxicity in mice, a pharmacological model of Alzheimer's disease (AD) with high predictive value for drug discovery. Here, as drug infusion is likely to better reflect drug bioavailability due to the interspecies pharmacokinetics variation, we analyzed the efficacy of FENM after chronic subcutaneous (SC) infusion, in comparison with IP injections in two AD mouse models, Aβ-injected mice and the transgenic APP/PSEN1 (APP/PS1) line.

Methods: In Aβ-treated mice, FENM was infused at 0.

View Article and Find Full Text PDF

T2DM detection methods are commonly used in teens and adults but are generally unsuitable to unborn fetuses in the context of non-invasive prenatal testing (NIPT). Biophysical and biochemical tests for fetuses are often invasive, carry risks, and have low sensitivity and specificity, with no direct method available to diagnose T2DM in utero. In contrast, cell-free DNA (cfDNA) is known have high sensitivity (93-98 %) and specificity (94-100 %) for cancer detection and fetal genetic disorders (trisomy 21, 8, and 13) making it applicable for fetal epigenetic and genetic analysis, including T2DM early detection.

View Article and Find Full Text PDF
Article Synopsis
  • - Somapacitan and recombinant human growth hormone (rhGH) are protein-based drugs used to manage growth disorders, but their use is banned in horseracing and equestrian sports due to performance-enhancing potential.
  • - The study developed a testing method using liquid chromatography high-resolution mass spectrometry (LC-HRMS) to distinguish between somapacitan and rhGH in horse plasma, identifying unique peptide fragments essential for differentiation.
  • - The testing method demonstrated high sensitivity (detection limits as low as 1 ng/mL) and was validated for reliability and precision, setting the stage for future trials and monitoring of these substances in equine athletes.
View Article and Find Full Text PDF
Article Synopsis
  • The study develops a high-throughput assay to measure peptides from type III procollagen in human serum, addressing limitations of existing immunoassays used for growth hormone detection.
  • The new method utilizes a combination of immunoaffinity enrichment and ultra-high-performance liquid chromatography-tandem mass spectrometry, resulting in good accuracy and precision for quantifying the peptides.
  • While this method shows a decent correlation to a standard immunoassay, significant bias indicates a need for standardized calibrators to improve result consistency across different laboratories.
View Article and Find Full Text PDF

Production of Domain 9 from the cation-independent mannose-6-phosphate receptor fused with an Fc domain.

Glycoconj J

December 2024

Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, Jiangsu, 214122, China.

Lysosomal storage diseases (LSDs) are genetic disorders caused by mutations in lysosomal enzymes, lysosomal membrane proteins or genes related to intracellular transport that result in impaired lysosomal function. Currently, the primary treatment for several LSDs is enzyme replacement therapy (ERT), which involves intravenous administration of the deficient lysosomal enzymes to ameliorate symptoms. The efficacy of ERT largely depends on the mannose-6-phosphate (M6P) modification of the N-glycans associated with the enzyme, as M6P is a marker for the recognition and trafficking of lysosomal enzymes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!